Skip to content

Annexon ANNX Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Vor Biopharma logo
Vor BiopharmaVOR
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's deferred tax assets and other non-current assets?
Annexon (ANNX) reported deferred tax assets and other non-current assets of $8.72M in Q1 2026.
How has Annexon's deferred tax assets and other non-current assets changed year-over-year?
Annexon's deferred tax assets and other non-current assets increased by 64.5% year-over-year, from $5.3M to $8.72M.